Tamoxifen bone

Posted: Deviant Date of post: 09-Feb-2019
<b>Tamoxifen</b> Impairs Both Longitudinal and Cortical <b>Bone</b>

Tamoxifen Impairs Both Longitudinal and Cortical Bone

The risk of osteoporosis and fracture influences the selection of adjuvant endocrine therapy. We analyzed bone mineral density (BMD) in Swiss patients of the Breast International Group (BIG) 1-98 trial [treatment arms: A, tamoxifen (T) for 5 years; B, letrozole (L) for 5 years; C, 2 years of T followed by 3 years of L; D, 2 years of L followed by 3 years of T]. Dual-energy X-ray absorptiometry (DXA) results were retrospectively collected. Repeated measures models using covariance structures allowing for different times between DXA were used to estimate changes in BMD. Prospectively defined covariates were considered as fixed effects in the multivariable models. Two hundred and sixty-one of 546 patients had one or more DXA with 577 lumbar and 550 hip measurements. Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and smoking. Treatment did not influence the occurrence of osteoporosis ( Aromatase inhibitors (AIs) are currently part of the standard endocrine therapy in postmenopausal women with early-stage endocrine-sensitive breast cancer [1]. In 2006, the large STAR clinical study concluded that raloxifene is equally effective in reducing the incidence of breast cancer, but after an average 4-year follow-up, although the difference was not statistically significant, there were 36% fewer uterine cancers and 29% fewer blood clots in women taking raloxifene than in women taking tamoxifen. Tamoxifen improves fertility in males with infertility by disinhibiting the hypothalamic–pituitary–gonadal axis (HPG axis) via ER antagonism and thereby increasing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and increasing testicular testosterone production. It is taken as a preventative measure in small doses, or used at the onset of any symptoms such as nipple soreness or sensitivity. Other drugs are taken for similar purposes such as clomifene and the anti-aromatase drugs which are used in order to try to avoid the hormone-related adverse effects. Occasionally tamoxifen is used in treatment of the rare conditions of retroperitoneal fibrosis A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and tibolone used to treat breast cancer significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects. Some cases of lower-limb lymphedema have been associated with the use of tamoxifen, due to the blood clots and deep vein thrombosis (DVT) that can be caused by this medication. Resolution of the blood clots or DVT is needed before lymphedema treatment can be initiated.

PREVENTION OF <b>BONE</b> LOSS AFTER WITHDRAWAL OF <b>TAMOXIFEN</b>

PREVENTION OF BONE LOSS AFTER WITHDRAWAL OF TAMOXIFEN

Your risk of osteoporosis (bone thinning) can be affected by breast cancer treatment and other treatments that lower your oestrogen levels. Osteoporosis is thinning of the bones so that they become more brittle. Our bones start to thin after the age of 35 or so, as part of the natural ageing process. Any cancer treatment in women that lowers oestrogen levels can increase the risk of osteoporosis. These treatments include: Tamoxifen for breast cancer usually only reduces bone density by a small amount. In postmenopausal women, aromatase inhibitors increase bone loss at an average rate of 1 to 3% per year. In young women who have had ovarian suppression followed by aromatase inhibitor therapy, bone density is lost at an average of 7 to 8% per year. Treatment with tamoxifen for 2 to 5 years before having aromatase inhibitors may slow down the rate of bone loss. Women who have had an early menopause (before the age of 45) due to cancer treatment or who have ovarian suppression therapy and aromatase inhibitors are at higher risk of bone loss. uses cookies to improve performance by remembering your session ID when you navigate from page to page. Please set your browser to accept cookies to continue. This cookie stores just a session ID; no other information is captured. Accepting the NEJM cookie is necessary to use the website.

The Truth About <i>Tamoxifen</i> Part 1 of 2

The Truth About Tamoxifen Part 1 of 2

Your bones support your body, give it shape, and help you move. Your bones also help protect your heart, lungs, and brain. Even though your bones feel hard and rigid, they are living tissues that constantly rebuild themselves during your life. During your childhood and teenage years, your body adds new bone faster than it gets rid of old bone. After about age 30, you can start to lose bone faster than your body makes it, which can weaken the bones and increase the risk of breakage. Some bone loss is natural as men and women age, but women are at higher risk of significant bone loss. Throughout your adult life, it’s important to take steps to make sure you don't lose too much bone and put yourself at risk of easily breaking a bone by falling or tripping. When you go through menopause, your levels of estrogen and other hormones drop sharply. This medication is used to: treat breast cancer that has spread to other parts of the body in men and women. I am sure your oncologist must be following you if its only been 2 yrs since you had radiation. Prostate cancers are generally amenable to radiation treatments and pts do very well. Treat early breast cancer in women who have already been treated with surgery, radiation, and/or chemotherapy. So check with your rad, oncologist ; an orthopod, as early DX means early treatment. Reduce the risk of developing a more serious type of breast cancer in women who have had ductal carcinoma in situ (dcis; a type of breast cancer This. A scapula is a very odd bone for a primary tumor, and also odd for something traveled to that bone, but it does no get bone spurs. However, it is more likely to be from some other place: lung, breast (w), prostate (m)... You should be evaluated for a rheumatologic condition like arthritis. Get a routine panel of blood tests and x rays, then more detailed tests depending on the outcome. Depending the cause, extent of disease, and location, radiation can reduce bone pain in 70% of patients treated. Read more See 1 more doctor answer It can if you have a stress fracture due to overuse. Radiation therapy is an effective means of relieving bone pain. You are young and should look into why you have low bone density.

Hormone Therapy for Breast Cancer Fact Sheet - National.
Hormone Therapy for Breast Cancer Fact Sheet - National.

For example, tamoxifen blocks the effects of estrogen in breast tissue but acts like estrogen in the uterus and bone. Other antiestrogen drugs, such as fulvestrant Faslodex®, work in a somewhat different way to block estrogen’s effects. In the women who received tamoxifen for the two years of the study, bone mineral density at the lumbar spine increased by 0.72 percent per year P = 0.01; in contrast, in the women who received.

Tamoxifen bone
Rating 4,7 stars - 833 reviews